Biomarkers for Ventilator-associated Pneumonia
Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia
Region Skane
1,000 participants
Oct 15, 2021
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05117125